

# CITATION REPORT

List of articles citing

## The Role of Cost-effectiveness Analysis in Health and Medicin

DOI: 10.1001/jama.1996.03540140060028  
JAMA - Journal of the American Medical Association,  
1996, 276, 1172.

**Source:** <https://exaly.com/paper-pdf/27520452/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
777	Assessing cost-effectiveness analyses in rheumatoid arthritis and osteoarthritis. <b>1997</b> , 10, 413-21		12
776	Cost-benefit & cost-effectiveness analysis of the rapid onset of selective serotonin reuptake inhibitors by augmentation. <b>1997</b> , 27, 377-90		5
775	EUR-ASSESS Project Subgroup report on Methodology. Methodological guidance for the conduct of health technology assessment. <b>1997</b> , 13, 186-219		43
774	Long-term health care outcomes in diabetes. Economic and political implications. <b>1997</b> , 26, 487-98		4
773	Reporting standards for clinical evaluation of new peripheral arterial revascularization devices. Technology Assessment Committee. <b>1997</b> , 8, 137-49		94
772	Patient-assessed health outcomes in chronic lung disease: what are they, how do they help us, and where do we go from here?. <b>1997</b> , 156, 1032-9		124
771	Clinicoeconomics in geropsychiatry. <b>1997</b> , 20, 219-40		2
770	Understanding the term "cost-effectiveness". <b>1997</b> , 9, 603-4		4
769	The perspective of a pharmacoeconomic study: targeting for audiences. <b>1997</b> , 35, 471-5		6
768	Theoretical issues in cost-effectiveness analysis. <b>1997</b> , 16, 121-8		71
767	Hospital care for persons with AIDS in the European Union. <b>1997</b> , 41, 157-76		13
766	Assessing Outcomes in Population Health: Moving the Field Forward. <b>1997</b> , 13, 3-5		14
765	Cost-effectiveness analysis of helicopter EMS for trauma patients. <b>1997</b> , 30, 500-6		78
764	Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. <b>1997</b> , 66, 454-63		37
763	A summary of economic evaluations published in the field of rheumatology and related disciplines. <b>1997</b> , 40, 1587-93		20
762	Cost-effectiveness analysis and nursing research--is there a fit?. <b>1998</b> , 30, 221-2		5
761	Milton Weinstein's insights on the development, use, and methodologic problems in cost-effectiveness analysis. <b>1998</b> , 30, 223-7		1

760	Methods for conducting and reporting cost-effectiveness analysis in nursing. <b>1998</b> , 30, 229-34		6
759	Cost-effectiveness analysis in the nursing literature, 1992-1996. <b>1998</b> , 30, 235-42		11
758	What to consider when conducting a cost-effectiveness analysis in a clinical setting. <b>1998</b> , 98, 1149-54		6
757	Prevalence-based economic evaluation. <i>Value in Health</i> , <b>1998</b> , 1, 251-9	3-3	47
756	The effectiveness of cost-effectiveness analysis in containing costs. <b>1998</b> , 13, 664-9		84
755	State-of-the-art principles and practices of medical economics. <b>1998</b> , 4, 491-7		6
754	Emergency department observation unit: can it be funded through reduced inpatient admission?. <b>1998</b> , 32, 670-5		15
753	Physician resource utilization in radiation oncology: a model based on management of carcinoma of the prostate. <b>1998</b> , 40, 593-603		10
752	Model for optimal space and staff efficiency in an otolaryngology clinic. <i>Otolaryngology - Head and Neck Surgery</i> , <b>1998</b> , 119, 394-7	5-5	2
751	Management of perioperative pain in hospitalized patients: a national survey. <b>1998</b> , 10, 77-85		54
750	The economics of febrile neutropenia: implications for the use of colony-stimulating factors. <b>1998</b> , 34, 1857-64		163
749	Improved health care resource utilization following video-EEG-confirmed diagnosis of nonepileptic psychogenic seizures. <b>1998</b> , 7, 385-90		208
748	Cost-effectiveness of tests to assess the risk of sudden death after acute myocardial infarction. <b>1998</b> , 31, 1490-2		5
747	The role of cost-consequence analysis in healthcare decision-making. <b>1998</b> , 13, 277-88		136
746	Development of an economic model for the management of upper gastrointestinal disease in primary care. Preliminary findings. <b>1998</b> , 14 Suppl 2, 11-23		7
745	Urge incontinence. Quality of life and patients' valuation of symptom reduction. <b>1998</b> , 14, 531-9		59
744	Economic Impact of Stroke and Implications for Interventions. <b>1998</b> , 9, 19-39		2
743	Evidence-based medicine and cost-effectiveness analysis. <b>1998</b> , 14, 525-37		12

742	Cardiac rehabilitation in the elderly. <b>1998</b> , 10, 273-83	1
741	The danger of applying group-level utilities in decision analyses of the treatment of localized prostate cancer in individual patients. <b>1998</b> , 18, 376-80	62
740	Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence. <b>1998</b> , 52, 586-94	9
739	Health economics and clinical pathology. <b>1998</b> , 51, 90-1	
738	Decentralised anticoagulant care. <b>1998</b> , 51, 89-90	14
737	Drug therapy: the impact of managed care. <b>1998</b> , 44, 1-32	
736	Book Reviews. <b>1998</b> , 18, 240-244	2
735	A systematic review of the cost-effectiveness of noncardiac transitional care units. <b>1998</b> , 113, 172-7	55
734	Medical Technology Assessment. <b>1998</b> , 87, 1271-1282	5
733	Medical technology assessment: an overview. <b>1998</b> , 87, 1271-82	28
732	Cancer Care in the Elderly: Cost and Quality-of-Life Considerations. <b>1998</b> , 5, 347-354	17
731	Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. <b>1999</b> , 16, 499-520	32
730	Equity in managed care for mental disorders. <b>1999</b> , 18, 22-31	28
729	Cost-effectiveness of regulations against using a cellular telephone while driving. <b>1999</b> , 19, 1-8	31
728	Quality of life and economic evaluation in SLE clinical trials. <b>1999</b> , 8, 645-54	34
727	Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria. <b>1999</b> , 53, 179-86	30
726	Assessing the cost-effectiveness of postmastectomy radiation therapy. <b>1999</b> , 44, 91-8	24
725	Towards a European consensus on conducting and reporting health economic evaluations--a report from the ISPOR Inaugural European Conference. <i>Value in Health</i> , <b>1999</b> , 2, 281-7	3-3 8

724	Cost-effectiveness of the diagnostic evaluation of vertigo. <b>1999</b> , 109, 600-5	41
723	Economic evaluation of cancer treatments: a review of the methods. <b>1999</b> , 11, 78-83	4
722	Covariation of physical and mental symptoms across illnesses: results of a factor analytic study. <b>1999</b> , 21, 122-7	8
721	Is the use of radiation therapy after mastectomy cost-effective?. <b>1999</b> , 9, 287-91	2
720	Economic consequences of the progression of rheumatoid arthritis in Sweden. <b>1999</b> , 42, 347-56	139
719	Effective follow-up strategies in soft tissue sarcoma. <b>1999</b> , 17, 83-7	46
718	Cost-effectiveness in Health and Medicine. By M.R. Gold, J.E Siegel, L.B. Russell, and M.C. Weinstein (eds). New York: Oxford University Press, 1996. <b>1999</b> , 2, 91-92	33
717	Measuring costs of guideline-driven mental health care: the Texas Medication Algorithm Project. <b>1999</b> , 2, 111-121	19
716	Costs and Benefits of Prevention and Disease Management. <b>1999</b> , 5, 153-166	20
715	Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine. <b>1999</b> , 19, 371-7	82
714	Health-related quality of life in economic evaluations for osteoporosis: whose values should we use?. <b>1999</b> , 19, 141-8	114
713	Raising the quality of cost-utility analyses: lessons learnt and still to learn. <b>1999</b> , 46, 217-38	42
712	The contingent valuation method in health care. <b>1999</b> , 47, 97-123	323
711	Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. <b>1999</b> , 354, 1457-63	349
710	Costing vascular surgery: A review of current reporting practice. <b>1999</b> , 30, 668-78	2
709	Cost-effectiveness of stress-echocardiography. <b>1999</b> , 17, 583-95, x	1
708	Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. The value of cost-effectiveness analyses for reimbursement decisions: perspectives from Medicare. <b>1999</b> , 137, S81-6	2
707	Finding answers to questions using cost analysis. <b>1999</b> , 70, 128-30	2

706	A systematic review of cost-effectiveness research of stroke evaluation and treatment. <b>1999</b> , 30, 1340-9	61
705	Is the societal perspective in cost-effectiveness analysis useful for decision makers?. <b>1999</b> , 25, 447-54	22
704	Hepatic resection for colorectal liver metastases: A cost-effectiveness analysis. <b>2000</b> , 232, 763-76	45
703	Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions. <b>2000</b> , 15, 439-45	30
702	A comparison of two methods for estimating the technical costs of external beam radiation therapy. <b>2000</b> , 47, 461-7	20
701	Cost-effectiveness of stress echocardiography and nuclear perfusion imaging. <b>2000</b> , 43, 197-214	1
700	Economic evaluation of alcohol treatment services. <b>2000</b> , 23, 27-39	38
699	Dietitian intervention improves lipid values and saves medication costs in men with combined hyperlipidemia and a history of niacin noncompliance. <b>2000</b> , 100, 218-24	38
698	Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. <b>2000</b> , 31, 1019-21	335
697	Quality of life and cost effectiveness analysis of therapy for locally recurrent rectal cancer. <b>2000</b> , 43, 1695-1701; discussion 1701-3	55
696	Ökonomische Evaluation der Rehabilitation: die Perspektive der Rentenversicherungsträger. <b>2000</b> , 8, 58-77	3
695	Cost reduction and quality improvement: it takes two to tango. <b>2000</b> , 28, 581-3	25
694	Assessing the quality of economic evaluations of health care interventions. <b>2000</b> , 11, 1513-5	2
693	Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology. <b>2000</b> , 11, 1591-5	32
692	Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma. <b>2000</b> , 18, 1474-80	22
691	Unstable preferences: a shift in valuation or an effect of the elicitation procedure?. <b>2000</b> , 20, 62-71	78
690	Economic evaluation of infection control practices in day care and the home: methodologic challenges and proposed solutions. <b>2000</b> , 19, S125-8	5
689	Costing interventions in primary care. <b>2000</b> , 17, 66-70	11

688	Cost-effectiveness of catheter ablation in patients with ventricular tachycardia. <b>2000</b> , 101, 280-8	28
687	American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. <b>2000</b> , 102, 126-40	565
686	Cost-utility analyses of clinical preventive services: published ratios, 1976-1997. <b>2000</b> , 19, 15-23	73
685	Costs for acute myocardial infarction in a tertiary care centre and nationwide in France. <b>2000</b> , 17, 603-9	11
684	Comparing cost-effectiveness analyses for the clinical oncology setting: the example of the Gynecologic Oncology Group 111 trial. <b>2000</b> , 18, 261-8	3
683	Health economics of contraception. <b>2000</b> , 27, 917-31, viii	5
682	COST-BENEFIT ANALYSIS FOR ALLERGEN IMMUNOTHERAPY. <b>2000</b> , 20, 593-607	3
681	Effect of allergist intervention on patient-centered and societal outcomes: allergists as leaders, innovators, and educators. <b>2000</b> , 106, 995-1018	17
680	American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. <b>2000</b> , 36, 326-40	276
679	Comparative cost effectiveness of varicella, hepatitis A, and pneumococcal conjugate vaccines. <b>2001</b> , 33, 639-45	20
678	Cost implications of specialized coagulation testing for acute ischemic stroke. <b>2001</b> , 10, 279-83	6
677	Accuracy of terminology and methodology in economic analyses in otolaryngology. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2001</b> , 124, 496-502	5.5 19
676	Decision analysis and its application in clinical medicine. <b>2001</b> , 94, 172-9	11
675	The art and science of incorporating cost effectiveness into evidence-based recommendations for clinical preventive services. <b>2001</b> , 20, 36-43	59
674	Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. <b>2001</b> , 357, 273-7	236
673	Methodological concerns and recommendations on policy consequences of the World Health Report 2000. <b>2001</b> , 357, 1692-7	94
672	Cost-Effectiveness Analyses: A Basic Overview for Dermatologists. <b>2001</b> , 5, 217-222	1
671	Patient preference for cancer therapy: an overview of measurement approaches. <b>2001</b> , 19, 220-30	137

670	Economics of end-of-life care in the intensive care unit. <b>2001</b> , 29, N46-51	52
669	Cost effectiveness of periradicular infiltration for sciatica: subgroup analysis of a randomized controlled trial. <b>2001</b> , 26, 2587-95	82
668	Pharmacoeconomic investigations in intensive care. <b>2001</b> , 7, 460-3	4
667	Cost analysis of dialysis modalities in Italy. <b>2001</b> , 14, 9-17	7
666	Pharmacogenomic testing: the cost factor. <b>2001</b> , 1, 171-4	28
665	Cost analysis of vaginal birth after cesarean. <b>2001</b> , 44, 571-87	5
664	Getting closer to the truth: overcoming research challenges when estimating the financial impact of worksite health promotion programs. <b>2001</b> , 15, 289-95	19
663	The utility of health states after stroke: a systematic review of the literature. <b>2001</b> , 32, 1425-9	187
662	Acknowledgment of uncertainty: a fundamental means to ensure scientific and ethical validity in clinical research. <b>2001</b> , 3, 389-95	49
661	Economic analysis of randomized, controlled trials. <b>2001</b> , 3, 396-403	5
660	Strategies for diagnosing and treating suspected acute bacterial sinusitis: a cost-effectiveness analysis. <b>2001</b> , 16, 701-11	33
659	[Analysis of the medico-economic literature comparing primary angioplasty and thrombolysis in the management of acute myocardial infarction]. <b>2001</b> , 50, 330-9	
658	Understanding economic analyses. <b>2001</b> , 2, 2-5	7
657	Cost-Effectiveness of a Trial of Labor After Previous Cesarean. <b>2001</b> , 97, 932-941	29
656	Cost-effectiveness of colorectal cancer screening. <b>2001</b> , 219, 44-50	29
655	Cost-effectiveness analysis in radiology. <b>2001</b> , 219, 611-20	57
654	The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA program. <b>2001</b> , 164, 2057-66	43
653	Decision analysis: a basic overview for the pediatric surgeon. <b>2002</b> , 11, 46-54	3



652	Understanding costs and cost-effectiveness in critical care: report from the second American Thoracic Society workshop on outcomes research. <b>2002</b> , 165, 540-50	141
651	Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness analysis. <b>2002</b> , 97, 803-10	75
650	Economic evaluation of bone morphogenetic protein versus autogenous iliac crest bone graft in single-level anterior lumbar fusion: an evidence-based modeling approach. <b>2002</b> , 27, S94-9	77
649	Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. <b>2002</b> , 113, 400-8	102
648	Economic considerations related to providing adequate pain relief for women in labour: comparison of epidural and intravenous analgesia. <b>2002</b> , 20, 305-18	9
647	Valuation of symptomatic hepatitis a in adults: estimates based on time trade-off and willingness-to-pay measurement. <b>2002</b> , 20, 739-47	23
646	Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. <b>2002</b> , 359, 1635-43	254
645	Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. <b>2002</b> , 359, 1980-9	173
644	A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990-2000. <b>2002</b> , 30, 145-52	143
643	Economic analysis in dermatology. <b>2002</b> , 46, 271-83	22
642	Do HEDIS measures reflect cost-effective practices?. <b>2002</b> , 23, 276-89	15
641	Cost-effectiveness of cataract surgery. Method to assess cost-effectiveness using registry data. <b>2002</b> , 28, 1742-9	44
640	Population screening for cancer-related germline gene mutations. <b>2002</b> , 3, 341-8	14
639	Cost-effectiveness analysis of colorectal cancer treatments. <b>2002</b> , 38, 953-63	22
638	Paying for prevention standardizing the measurement of the value of health care interventions. <b>2002</b> , 29, 613-43, v	
637	Análisis coste-consecuencia de un centro de día psicogeriatrico. <b>2002</b> , 37, 291-297	3
636	Economic Analysis and Clinical Research. <b>2002</b> , 275-304	
635	Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. <b>2002</b> , 20, 9-16	48

634	Priority setting for new technologies in medicine: a transdisciplinary study. <b>2002</b> , 2, 14		17
633	EFNEP: a nutrition education program that demonstrates cost-benefit. <b>2002</b> , 102, 39-45		72
632	Pharmacoeconomics of coxib therapy. <b>2002</b> , 24, S28-37		7
631	The distribution problem in economic evaluation: income and the valuation of costs and consequences of health care programmes. <b>2002</b> , 11, 55-70		50
630	Der who weltgesundheitsbericht 2000 Anspruch und kritische wrdigung. <b>2002</b> , 10, 276-288		2
629	The limited incorporation of economic analyses in clinical practice guidelines. <b>2002</b> , 17, 210-20		20
628	Pharmaco-economics of blood transfusion safety: review of the available evidence. <b>2002</b> , 83, 146-55		51
627	Economic evaluation in long-term clinical trials. <b>2002</b> , 21, 2879-88		10
626	Empiric beta-blockers for the prophylaxis of variceal hemorrhage: cost effective or clinically applicable?. <b>2003</b> , 37, 249-52		4
625	Patient and community preferences for treatments and health states in multiple sclerosis. <b>2003</b> , 9, 311-9		39
624	Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. <b>2003</b> , 97, 3099-106		36
623	A utility-theoretic model for QALYs and willingness to pay. <b>2003</b> , 12, 17-31		23
622	An exploratory instrumental variable analysis of the outcomes of localized breast cancer treatments in a medicare population. <b>2003</b> , 12, 171-86		42
621	Value in health: "bridging the gap" among our disciplines. <i>Value in Health</i> , <b>2003</b> , 6, 1-2	3.3	2
620	The impact of including passive benefits in cost-effectiveness analysis: the case of automated external defibrillators on commercial aircraft. <i>Value in Health</i> , <b>2003</b> , 6, 466-73	3.3	9
619	Transurethral resection vs microwave thermotherapy of the prostate: a cost-consequences analysis. <b>2003</b> , 92, 713-8		41
618	34th Bethesda Conference: Task force #5--Is atherosclerosis imaging cost effective?. <b>2003</b> , 41, 1906-17		39
617	Priority setting in a hospital drug formulary: a qualitative case study and evaluation. <b>2003</b> , 66, 295-303		41

616	Reporting standards for clinical evaluation of new peripheral arterial revascularization devices. <b>2003</b> , 14, S395-404	136
615	Chronic Disease Management. <b>2003</b> , 11, 477-488	63
614	Entscheidungsanalytische Evaluationen gesundheitsökonomischer Endpunkte von Interventionen bei koronarer Herzkrankheit [Definitionen, Methoden und Fallbeispiele. <b>2003</b> , 1, 3-16	1
613	Discounting in cost-utility analysis of healthcare interventions: reassessing current practice. <b>2003</b> , 21, 75-87	12
612	Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. <b>2003</b> , 21, 477-96	48
611	Switching therapy in health economics trials: confronting the confusion. <b>2003</b> , 23, 335-40	5
610	An ethical template for pharmacy benefits. <b>2003</b> , 22, 125-37	36
609	Commentary. <b>2003</b> , 60, 100S-112S	2
608	Research ethics and law of healthcare system quality improvement: the conflict of cost containment and quality. <b>2003</b> , 31, S143-52	19
607	Cost-effective Antiemesis. <b>2003</b> , 41, 145-64	7
606	Should radon be reduced in homes? A cost-effect analysis. <b>2003</b> , 84, 227-35	19
605	Economic evaluation of new therapies in critical illness. <b>2003</b> , 31, S7-16	52
604	It is money that matters: decision analysis and cost-effectiveness analysis. <b>2003</b> , 106-16	23
603	Economic Analysis of the Use of Limited Coronal Computed Tomography Scans in the Management of Sinusitis. <b>2004</b> , 18, 329-334	6
602	Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection. <b>2004</b> , 233, 729-39	45
601	Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. <b>2004</b> , 96, 316-25	59
600	A Swedish cost-effectiveness analysis of community-based Chlamydia trachomatis PCR testing of postal urine specimens obtained at home. <b>2004</b> , 32, 324-32	8
599	Acceptance and rejection: cost-effectiveness and the working nephrologist. <b>2004</b> , 66, 1735-41	11

598	Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. <i>Value in Health</i> , <b>2004</b> , 7, 518-28	3-3	537
597	Setting priorities in health care organizations: criteria, processes, and parameters of success. <b>2004</b> , 4, 25		91
596	Integrating ethical enquiry and health technology assessment: limits and opportunities for efficiency and equity. <b>2004</b> , 2, 103-117		8
595	Cost efficiency of nuclear cardiology services in the modern health care environment. <b>2004</b> , 6, 41-52		2
594	The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals. <b>2004</b> , 101, 189-97		17
593	Critical appraisal of published economic evaluations of home care for the elderly. <b>2004</b> , 39, 255-67		2
592	The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. <b>2004</b> , 50, 129-46		59
591	The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. <b>2004</b> , 15, 526-36		99
590	Impact of ventilator-associated pneumonia on resource utilization and patient outcome. <b>2004</b> , 25, 1090-6		67
589	Análisis coste-efectividad en procesos que requieren ventilación mecánica. Estudio de los GRD 475 y 483. <b>2004</b> , 28, 349-355		2
588	Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery. <b>2004</b> , 22, 885-94		20
587	Pharmacoeconomic implications of new therapies in sepsis. <b>2004</b> , 22, 895-906		46
586	Cost-utility analysis for endoscopic sinus surgery. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2004</b> , 130, 31-8	5-5	17
585	The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis. <b>2004</b> , 116, 451-9		22
584	ROC curves in clinical chemistry: uses, misuses, and possible solutions. <b>2004</b> , 50, 1118-25		237
583	Economic evaluation in total hip arthroplasty: analysis and review of the literature. <b>2004</b> , 19, 180-9		78
582	Comparison of the deep inferior epigastric perforator flap and free transverse rectus abdominis myocutaneous flap in postmastectomy reconstruction: a cost-effectiveness analysis. <b>2004</b> , 113, 1650-61		83
581	Effect of raloxifene on quality of life: a prospective study using the Utian Quality of Life (UQOL) Scale. <b>2004</b> , 11, 275-80		15

580	Cost-utility analysis of orthoptic screening in kindergarten: a Markov model based on data from Germany. <b>2004</b> , 113, e95-108	19
579	Cost-utility and cost-benefit analyses: how did we get here and where are we going?. <b>2004</b> , 16, 527-34	23
578	Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls. <b>2004</b> , 16, 519-26	27
577	Economic evaluation of a comprehensive self-management programme in patients with moderate to severe chronic obstructive pulmonary disease. <b>2004</b> , 1, 7-16	35
576	Is simvastatin cost-effective for reducing the risk of vascular events?. <b>2005</b> , 1, 86-87	
575	Estimating the Opportunity Costs of Osteoporosis in the United States. <b>2005</b> , 21, 4-16	16
574	Use of time studies for determining intervention costs. <b>2005</b> , 54, 280-4	14
573	Can the Nation Afford ICDs for All Patients With Severe Cardiomyopathy?. <b>2005</b> , 14, 36-41	
572	The evaluation of rectal bleeding in adults. A cost-effectiveness analysis comparing four diagnostic strategies. <b>2005</b> , 20, 81-90	15
571	Priority setting in hospitals: fairness, inclusiveness, and the problem of institutional power differences. <b>2005</b> , 61, 2355-62	82
570	Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. <b>2005</b> , 5, 130	55
569	Elective cesarean section to prevent anal incontinence and brachial plexus injuries associated with macrosomia--a decision analysis. <b>2005</b> , 16, 19-28; discussion 28	45
568	Analysis of aspirin-associated risks in healthy individuals. <b>2005</b> , 39, 51-7	5
567	Quality of abstracts of papers reporting original cost-effectiveness analyses. <b>2005</b> , 25, 424-8	25
566	Decision analysis and simulation modeling for evaluating diagnostic tests on the basis of patient outcomes. <b>2005</b> , 185, 581-90	13
565	Towards optimal surgical outcomes. <b>2005</b> , 5, 741-9	1
564	Integrating preferences into health status assessment for amyotrophic lateral sclerosis: the ALS Utility Index. <b>2005</b> , 6, 169-76	13
563	Screening for gestational diabetes mellitus: a decision and cost-effectiveness analysis of four screening strategies. <b>2005</b> , 28, 1482-4	30

562	Assessing the benefit of radiation therapy after breast-conserving surgery for ductal carcinoma-in-situ. <b>2005</b> , 23, 5171-7		21
561	Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans. <b>2005</b> , 23, 8877-83		31
560	Patient satisfaction and information gain after the preanesthetic visit: a comparison of face-to-face interview, brochure, and video. <b>2005</b> , 100, 1753-1758		72
559	Measuring the health consequences of alcohol consumption: current needs and methodological challenges. <b>2005</b> , 23, 162-9		6
558	The Cost of Illness, Disability, and Premature Mortality to Russia's Economy. <b>2005</b> , 46, 495-524		6
557	A synthesis of cost-utility analysis literature in infectious disease. <b>2005</b> , 5, 383-91		15
556	Challenges in creating a good randomized controlled trial in hand surgery. <b>2005</b> , 32, 563-73, vii		14
555	Implications of spillover effects within the family for medical cost-effectiveness analysis. <b>2005</b> , 24, 751-73		108
554	Cost-utility analysis of tympanomastoidectomy for adults with chronic suppurative otitis media. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2005</b> , 133, 352-6	5.5	9
553	Cost effectiveness of chest computed tomography after lung cancer resection: a decision analysis model. <b>2005</b> , 80, 1215-22; discussion 1222-3		29
552	Cost-effectiveness analysis in the assessment of diagnostic imaging technologies. <b>2005</b> , 235, 361-70		59
551	Methodologic issues in the comparison of microsurgical flaps/techniques in head and neck reconstruction. <b>2005</b> , 32, 347-59, vi		8
550	Quality-of-life valuations of advanced breast cancer by New Zealand women. <b>2006</b> , 24, 281-92		17
549	Quality-of-life valuations of advanced breast cancer by New Zealand women. <b>2006</b> , 24, 415-6; author reply 416-7		2
548	Cálculo de la eficiencia de oportunidad de los nuevos medicamentos. <b>2006</b> , 3, 3-5		1
547	Do oncologists believe new cancer drugs offer good value?. <b>2006</b> , 11, 90-5		151
546	Preoperative use of mupirocin for the prevention of healthcare-associated Staphylococcus aureus infections: a cost-effectiveness analysis. <b>2006</b> , 27, 1304-12		33
545	Primer: using decision analysis to improve clinical decision making in urology. <b>2006</b> , 3, 439-48		11

544	Cost effectiveness of bempiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis. <b>2006</b> , 24, 81-92		22
543	An evaluation of emergency physician selection of observation unit patients. <b>2006</b> , 24, 271-9		26
542	The role of tubal reconstructive surgery in the era of assisted reproductive technologies. <b>2006</b> , 86, S31-4		4
541	Economic analysis in hand surgery. <b>2006</b> , 31, 664-8		7
540	Healthcare costs and long-term outcomes after acute respiratory distress syndrome: A phase III trial of inhaled nitric oxide. <b>2006</b> , 34, 2883-90		100
539	A cost/utility analysis of open reduction and internal fixation versus cast immobilization for acute nondisplaced mid-waist scaphoid fractures. <b>2006</b> , 117, 1223-35; discussion 1236-8		79
538	Financing and cost-effectiveness analysis of public-private partnerships: provision of tuberculosis treatment in South Africa. <b>2006</b> , 4, 11		22
537	Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. <i>Value in Health</i> , <b>2006</b> , 9, 77-89	3.3	48
536	Trends in the measurement of health utilities in published cost-utility analyses. <i>Value in Health</i> , <b>2006</b> , 9, 213-8	3.3	102
535	A primer on economic evaluations related to expansion of newborn screening for genetic and metabolic disorders. <b>2006</b> , 35, 692-9		4
534	Economic Valuation of Health for Environmental Policy: Comparing Alternative Approaches. Introduction and Overview. <b>2006</b> , 34, 339-346		9
533	A review of health care models for coronary heart disease interventions. <b>2006</b> , 9, 311-24		19
532	Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers: What can we learn from clinical research?. <i>European Journal of Health Economics</i> , <b>2006</b> , 7, 129-35	3.6	5
531	Economic evaluation of alternative strategies to treat patients with diabetes mellitus and coronary artery disease. <b>2006</b> , 97, 59G-65G		5
530	A Markov computer simulation model of the economics of neuromuscular blockade in patients with acute respiratory distress syndrome. <b>2006</b> , 6, 15		6
529	The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health--National Heart, Lung, and Blood Institute--sponsored Women's Ischemia Syndrome Evaluation. <b>2006</b> , 114, 894-904		235
528	A Financial Cost-Benefit Analysis of a Health Promotion Program for Individuals With Mobility Impairments. <b>2006</b> , 16, 220-228		10
527	Cost-effectiveness of drug-eluting stents: real-world scrutiny of the BASKET trial of real-world usage. <b>2006</b> , 3, 305-9		2

526	The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. <b>2006</b> , 29, 259-64	44
525	Validation of the Subjective Numeracy Scale: effects of low numeracy on comprehension of risk communications and utility elicitations. <b>2007</b> , 27, 663-71	235
524	Costs and cost-effectiveness of a low-intensity patient-directed intervention to promote colorectal cancer screening. <b>2007</b> , 25, 5248-53	29
523	Cost-return prediction in morbidly obese employees following weight loss interventions: a study framework. <b>2007</b> , 2007, 1766-9	
522	Strategies to prevent varicella among newly arrived adult immigrants and refugees: a cost-effectiveness analysis. <b>2007</b> , 44, 1040-8	23
521	Simplified pharmacoeconomics of critical care and severe sepsis. <b>2007</b> , 22, 283-93	3
520	Quality-of-life assessment when there is a loss of income. <b>2007</b> , 27, 27-33	14
519	Interpreting the economic literature in oncology. <b>2007</b> , 25, 196-202	24
518	Medicare and cost-effectiveness analysis: time to ask the taxpayers. <b>2007</b> , 26, 1399-406	27
517	Estimating preference scores in conventional and home nocturnal hemodialysis patients. <b>2007</b> , 2, 477-83	10
516	Strengthening the status of psychotherapy for personality disorders: an integrated perspective on effects and costs. <b>2007</b> , 52, 803-10	19
515	United Kingdom cervical cancer screening and the costs of time and travel. <b>2007</b> , 23, 232-9	12
514	Does providing cost-effectiveness information change coverage priorities for citizens acting as social decision makers?. <b>2007</b> , 83, 65-72	16
513	Cost effectiveness of an adherence-improving programme in hypertensive patients. <b>2007</b> , 25, 239-51	23
512	Health utilities using the EQ-5D in studies of cancer. <b>2007</b> , 25, 365-84	199
511	Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children: theoretical and methodological considerations. <b>2007</b> , 25, 713-26	86
510	An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation. <b>2007</b> , 23, 2071-81	7
509	Measuring health-related quality of life for child maltreatment: a systematic literature review. <b>2007</b> , 5, 42	39



508	Choice of modelling technique for evaluating health care interventions. <b>2007</b> , 58, 168-176	45
507	Tools for Assessment of Cardiovascular Tests and Therapies. <b>2007</b> , 1-34	
506	Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. <b>2007</b> , 46, 1049-56	47
505	Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. <b>2007</b> , 109, 1011-8	154
504	Cost effectiveness of mammography screening for Chinese women. <b>2007</b> , 110, 885-95	50
503	Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. <b>2008</b> , 158, 351-9	60
502	A cost-utility analysis of treatments for malignant liver tumours: a pilot project. <b>2007</b> , 9, 42-51	3
501	Epidemiologic guidance with coronary artery calcium scoring. <b>2008</b> , 10, 60-6	2
500	Economic evaluation of sacral nerve stimulation for faecal incontinence. <b>2008</b> , 95, 1155-63	60
499	Pharmacoeconomics is coming of age. <b>2008</b> , 84, 188-90	2
498	Quality-initiated prophylactic antibiotic use in laparoscopic-assisted vaginal hysterectomy. <b>2008</b> , 48, 592-5	14
497	Valuation of the SF-6D Health States Is Feasible, Acceptable, Reliable, and Valid in a Chinese Population. <i>Value in Health</i> , <b>2008</b> , 11, 295-303	3-3 93
496	Perceptions of quality-of-life effects of treatments for diabetes mellitus in vulnerable and nonvulnerable older patients. <b>2008</b> , 56, 1183-90	26
495	Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?. <b>2008</b> , 58, 231-44	65
494	Breast cancer screening and dialysis: too much or too little. <b>2008</b> , 52, 830-3	2
493	A primer on critical care pharmacy services. <b>2008</b> , 42, 1871-81	20
492	A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease. <b>2008</b> , 28, 291-303	10
491	Cost-effectiveness analysis of management strategies for obscure GI bleeding. <b>2008</b> , 68, 920-36	100

490	The role of tubal reconstructive surgery in the era of assisted reproductive technologies. <b>2008</b> , 90, S250-3	14
489	The use of cost-effectiveness analysis in plastic surgery clinical research. <b>2008</b> , 35, 285-96	36
488	Evaluating the cost-effectiveness of anterior uveitis investigation by Canadian ophthalmologists. <b>2008</b> , 43, 652-7	9
487	Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?. <b>2008</b> , 15, 608-15	19
486	Twenty years of cost-effectiveness analysis in medical imaging: are we improving?. <b>2008</b> , 249, 917-25	37
485	Calculation of prevalence with Markov models: budget impact analysis of thrombolysis for stroke. <b>2008</b> , 28, 481-90	17
484	Erythropoietic agents for anemia of critical illness. <b>2008</b> , 65, 540-6	8
483	Costs and state-specific rates of thoracic and lumbar vertebroplasty, 2001-2005. <b>2008</b> , 33, 1905-12	20
482	A comparison of the superficial inferior epigastric artery flap and deep inferior epigastric perforator flap in postmastectomy reconstruction: A cost-effectiveness analysis. <b>2008</b> , 16, 77-84	17
481	Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. <b>2008</b> , 3, e4057	42
480	[Economic evaluation in health: applications in infectious diseases]. <b>2009</b> , 25, 2543-52	18
479	Using observational data for decision analysis and economic analysis. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2009</b> , 91 Suppl 3, 73-9	5.6 19
478	Personal and societal health quality lost to tuberculosis. <b>2009</b> , 4, e5080	41
477	Cost-effectiveness of prophylactic surgery for duodenal cancer in familial adenomatous polyposis. <b>2009</b> , 18, 2677-84	2
476	ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease), developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; America. <b>2009</b> , 120, e100-26	21
475	Cost, effectiveness, and cost-effectiveness. <b>2009</b> , 2, 49-54	27
474	Racial/ethnic differences in concerns about current and future medications among patients with type 2 diabetes. <b>2009</b> , 32, 311-6	59
473	Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. <b>2009</b> , 27, 953-9	19

472	Has the time come for cost-effectiveness analysis in US health care?. <b>2009</b> , 4, 425-43		21
471	Decision Analysis and Cost-effectiveness Analysis. <b>2009</b> , 21, 216-222		28
470	Evaluating the cost-effectiveness of cancer patient navigation programs: conceptual and practical issues. <b>2009</b> , 115, 5394-403		37
469	Cost utility analysis of knee prosthesis with complete microprocessor control (C-leg) compared with mechanical technology in trans-femoral amputees. <i>European Journal of Health Economics</i> , <b>2009</b> , 10, 47-55	3.6	47
468	Cost effectiveness of internet interventions: review and recommendations. <b>2009</b> , 38, 40-5		185
467	Lessons for non-VA care delivery systems from the U.S. Department of Veterans Affairs Quality Enhancement Research Initiative: QUERI Series. <b>2009</b> , 4, 9		20
466	Assessment of transparency of cost estimates in economic evaluations of patient safety programmes. <b>2009</b> , 15, 451-9		27
465	Decision making in implant dentistry: an evidence-based and decision-analysis approach. <b>2009</b> , 50, 154-72		25
464	Cost-effectiveness of routine and group programs for treatment of obese children. <b>2009</b> , 51, 606-11		14
463	Cost-effectiveness of screening for unhealthy alcohol use with % carbohydrate deficient transferrin: results from a literature-based decision analytic computer model. <b>2009</b> , 33, 1440-9		13
462	Ultrasound-guided central line placement as compared with standard landmark technique: some unpleasant arithmetic for the economics of medical innovation. <i>Value in Health</i> , <b>2009</b> , 12, 98-100	3.3	7
461	Deriving a patient-based utility index from a cancer-specific quality of life questionnaire. <i>Value in Health</i> , <b>2009</b> , 12, 800-7	3.3	10
460	Preliminary validation of an optimally weighted patient-based utility index by application to randomized trials in breast cancer. <i>Value in Health</i> , <b>2009</b> , 12, 967-76	3.3	3
459	The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. <i>Value in Health</i> , <b>2009</b> , 12, 1086-99	3.3	55
458	The cost-effectiveness of nonsurgical versus surgical treatment for carpal tunnel syndrome. <b>2009</b> , 34, 1193-200		34
457	Cost-effectiveness analysis of ED decision making in patients with non-high-risk heart failure. <b>2009</b> , 27, 293-302		34
456	ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease); developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation, America. <b>2009</b> , 54, 1356-63		44
455	Extended Dalteparin Prophylaxis for Venous Thromboembolic Events. <b>2009</b> , 9, 44-58		10

454	Racial and ethnic differences in preferences for health states and the implications for cost-utility analysis. <b>2009</b> , 9, 365-73	2
453	A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer. <b>2009</b> , 32, 49-55	25
452	Reducing hospital expenditures with the COPE (Creating Opportunities for Parent Empowerment) program for parents and premature infants: an analysis of direct healthcare neonatal intensive care unit costs and savings. <b>2009</b> , 33, 32-7	58
451	Survival and outcome of neurosurgical patients requiring ventilatory support after intensive care unit stay. <b>2009</b> , 65, 530-7; discussion 537-8	11
450	An economic analysis of hand transplantation in the United States. <b>2010</b> , 125, 589-598	66
449	Fundamental principles of conducting a surgery economic analysis study. <b>2010</b> , 125, 727-735	31
448	Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. <b>2010</b> , 54, 258-68	49
447	Assessing security measures reducing terrorist risk: inverse ex post cost-benefit and cost-effectiveness analyses of Norwegian airports and seaports. <b>2010</b> , 3, 179-195	17
446	Breast cancer-related preferences among women with and without BRCA mutations. <b>2010</b> , 119, 177-84	20
445	The challenges of cost-effectiveness analyses for the clinician. <b>2010</b> , 56, 1023-5	0
444	Health economics of blood transfusion safety--focus on sub-Saharan Africa. <b>2010</b> , 38, 53-8	18
443	Willingness-to-pay to avoid the time spent and discomfort associated with screening colonoscopy. <b>2010</b> , 19, 1193-211	15
442	Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema--a long-term analysis from a Swiss perspective. <b>2010</b> , 10, 4	18
441	Cost-effectiveness analysis in infectious diseases. <b>2010</b> , 16, 1705-6	1
440	The value of specialty oncology drugs. <b>2010</b> , 45, 115-32	42
439	Budget impact analysis of thrombolysis for stroke in Spain: a discrete event simulation model. <i>Value in Health</i> , <b>2010</b> , 13, 69-76	3-3 39
438	Preference-based quality of life of end-stage ankle arthritis treated with arthroplasty or arthrodesis. <b>2010</b> , 31, 563-6	46
437	Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis. <b>2010</b> , 28, 119-25	25

436	Theoretical foundation of patient v. population preferences in calculating QALYs. <b>2010</b> , 30, E57-63	39
435	Single-dose versus multiple-dose antibiotic prophylaxis for the surgical treatment of closed fractures. <b>2010</b> , 81, 256-62	25
434	A time tradeoff method for eliciting partner's quality of life due to patient's health states in prostate cancer. <b>2010</b> , 30, 355-65	34
433	The cost-effectiveness of a nonpharmacologic intervention for individuals with dementia and family caregivers: the tailored activity program. <b>2010</b> , 18, 510-9	78
432	A cost-utility analysis of nonsurgical management, total wrist arthroplasty, and total wrist arthrodesis in rheumatoid arthritis. <b>2010</b> , 35, 379-391.e2	64
431	Economic effects of pharmacists on health outcomes in the United States: A systematic review. <b>2010</b> , 67, 1624-34	102
430	Estimation of a valuation function for a diabetes mellitus-specific preference-based measure of health: the Diabetes Utility Index. <b>2010</b> , 28, 201-16	10
429	Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review. <b>2010</b> , 28, 521-38	28
428	Cost-effectiveness analysis in markets with high fixed costs. <b>2010</b> , 28, 867-75	2
427	A review and critique of studies reporting utility values for schizophrenia-related health states. <b>2010</b> , 28, 1109-21	14
426	Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. <b>2010</b> , 14, 375-84	36
425	Demythologizing the high costs of pharmaceutical research. <b>2011</b> , 6, 34-50	120
424	Cost-effectiveness analysis of the most common orthopaedic surgery procedures: knee arthroscopy and knee anterior cruciate ligament reconstruction. <b>2011</b> , 27, 1317-22	78
423	Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases. <b>2011</b> , 47, 2291-8	9
422	A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID). <b>2011</b> , 104, 383-9	76
421	Pharmacoeconomy: an indispensable tool for the rationalization of health costs. <b>2011</b> , 47, 231-240	7
420	The effect of pulmonary artery catheter use on costs and long-term outcomes of acute lung injury. <b>2011</b> , 6, e22512	31
419	Pharmacoeconomics. 166-176	

418	Economic analysis of the military health professions scholarship program for neurosurgeons. <b>2011</b> , 69, 525-31; discussion 531-2	5
417	Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria?. <b>2011</b> , 13, 783-91	22
416	Cost-effectiveness model for youth EFNEP programs: what do we measure and how do we do it?. <b>2011</b> , 43, 295-302	3
415	Triglyceride to HDL ratio is a reliable predictor of adverse outcomes in risk stratification for candidates undergoing abdominal aortic surgery. <b>2011</b> , 41, 249-55	2
414	Health state utility values in patients undergoing endoscopic sinus surgery. <b>2011</b> , 121, 2672-8	143
413	References. <b>2011</b> , 481-517	
412	How appropriate are cerebrospinal fluid polymerase chain reaction requests for suspected central nervous system infections?. <b>2011</b> , 11, 554-7	2
411	Economic evaluation of caffeine for apnea of prematurity. <b>2011</b> , 127, e146-55	31
410	Cost-Effectiveness Analysis of Unicompartmental Knee Arthroplasty and High Tibial Osteotomy for Treatment of Medial Compartmental Osteoarthritis. <b>2011</b> , 1, 27-37	3
409	Improving patient access to cancer drugs in India: Using economic modeling to estimate a more affordable drug cost based on measures of societal value. <b>2011</b> , 27, 23-30	12
408	Health outcomes in economic evaluation: who should value health?. <b>2011</b> , 97, 197-210	41
407	Cost-effectiveness model of endoscopic biopsy for eosinophilic esophagitis in patients with refractory GERD. <b>2011</b> , 106, 1439-45	40
406	Economic Evaluation With Clinical Trials in Neonatology. <b>2011</b> , 12, e69-e75	6
405	Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis. <b>2011</b> , 8, e1001063	42
404	Impact of program scale and indirect effects on the cost-effectiveness of vaccination programs. <b>2012</b> , 32, 442-6	7
403	Financial relationships in economic analyses of targeted therapies in oncology. <b>2012</b> , 30, 1316-20	35
402	The cost-effectiveness of biopharmaceuticals: a look at the evidence. <b>2012</b> , 4, 281-8	9
401	Cost-effectiveness in otolaryngology. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2012</b> , 147, 180-1; author reply 181	5.5

400	Health care costs: how do we decide value? When do we decide? How do we particularize the decisions?. <b>2012</b> , 17, 157-9	4
399	Incremental benefits and cost of coordinated anxiety learning and management for anxiety treatment in primary care. <b>2012</b> , 42, 1937-48	20
398	Preferences for cancer treatments: an overview of methods and applications in oncology. <b>2012</b> , 23, 1104-1110	73
397	Reduced length of stay in hospital for burn patients following a change in practice guidelines: financial implications. <b>2012</b> , 33, e275-9	19
396	The cost effectiveness of single-level instrumented posterolateral lumbar fusion at 5 years after surgery. <b>2012</b> , 37, 769-74	76
395	. <b>2012</b> ,	
394	Performing a cost analysis in spine outcomes research: comparing ventral and dorsal approaches for cervical spondylotic myelopathy. <b>2012</b> , 70, 860-7; discussion 867	48
393	Perspectives on cost-effective medicine and the use of cost-effectiveness analyses. <b>2012</b> , 54, 2-3	3
392	Displaced humeral lateral condyle fractures in children: should we bury the pins?. <b>2012</b> , 32, 573-8	34
391	Here it comes....the role of cost-effective analysis. <b>2012</b> , 127, 265-6	1
390	Economic aspects and evidence-based decision making in evaluating patients with suspected small bowel disorders. <b>2012</b> , 14, 123-128	0
389	The economics of antimicrobial stewardship: the current state of the art and applying the business case model. <b>2012</b> , 33, 389-97	21
388	Acellular dermal matrices: economic considerations in reconstructive and aesthetic breast surgery. <b>2012</b> , 39, 187-216	19
387	Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy. <b>2012</b> , 53, 2371-7	21
386	[Pharmaco-economic aspects of perioperative pain management]. <b>2012</b> , 31, 60-6	2
385	Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. <b>2012</b> , 56, 1089-1096	48
384	The cost effectiveness of newer epilepsy treatments: a review of the literature on partial-onset seizures. <b>2012</b> , 30, 903-23	12
383	Health care and lost productivity costs of overweight and obesity in New Zealand. <b>2012</b> , 36, 550-6	42

382	The cost effectiveness of radiofrequency ablation for Barrett's esophagus. <b>2012</b> , 143, 567-575	124
381	Small bowel endoscopy: cost-effectiveness of the different approaches. <b>2012</b> , 26, 325-35	12
380	The high cost of cancer drugs and what we can do about it. <b>2012</b> , 87, 935-43	143
379	Methodological considerations in cost of illness studies on Alzheimer disease. <b>2012</b> , 2, 18	47
378	The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs. <b>2012</b> , 18, 343-51	6
377	Health-related quality of life in adolescents with or at risk for type 2 diabetes mellitus. <b>2012</b> , 160, 911-7	26
376	Cost-effectiveness analysis of human resources policy interventions to address the shortage of nurses in rural South Africa. <b>2012</b> , 75, 801-6	21
375	Econometric studies on pharmacist care services are lacking--a call for papers. <b>2012</b> , 20, 69-70	
374	Cost-Effectiveness Analysis and Cost-Benefit Analysis. <b>2013</b> , 288-306	
373	Quality of life among obese patients seeking weight loss surgery: the importance of obesity-related social stigma and functional status. <b>2013</b> , 28, 231-8	48
372	Cost analysis of open radical cystectomy versus robot-assisted radical cystectomy. <b>2013</b> , 14, 26-31	33
371	Cost-effectiveness analysis for imaging techniques with a focus on cardiovascular magnetic resonance. <b>2013</b> , 15, 52	17
370	Cost-effectiveness of spinal cord stimulation therapy in management of chronic pain. <b>2013</b> , 14, 1631-49	102
369	What does breast cancer treatment cost and what is it worth?. <b>2013</b> , 27, 829-41, ix	8
368	Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer. <b>2013</b> , 20, 2873-80	53
367	A community-based intervention for primary prevention of cardiovascular diseases in the slums of Nairobi: the SCALE UP study protocol for a prospective quasi-experimental community-based trial. <b>2013</b> , 14, 409	17
366	The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review. <b>2013</b> , 31, 1131-54	16
365	The contribution of the HIV specialist nurse to HIV care: a scoping review. <b>2013</b> , 22, 3349-60	9



364	Valutazione economica del sistema di aferesi per la rimozione di granulociti e macrofagi (Adacolumn®) rispetto a biologico nel trattamento della colite ulcerosa moderata-severa in pazienti steroide-dipendenti o resistenti in Italia. <b>2013</b> , 6, 55-64		
363	Analisi di cost-consequence della duplice e triplice terapia nel trattamento dell'epatite cronica di tipo C genotipo 1 in pazienti adulti naïve con fibrosi F0F2. <b>2013</b> , 15, 111-122		1
362	Tools for Assessment of Cardiovascular Tests and Therapies. <b>2013</b> , 1-32		
361	Eight questions about cost. <b>2013</b> , 66, 1824-7		1
360	Cost of intraocular lens versus contact lens treatment after unilateral congenital cataract surgery: retrospective analysis at age 1 year. <b>2013</b> , 120, 14-9		23
359	Poor health-related quality of life prior to ECT in depressed patients normalizes with sustained remission after ECT. <b>2013</b> , 147, 107-11		18
358	Design of a cluster-randomized controlled trial of a diabetes prevention program within African-American churches: The Fit Body and Soul study. <b>2013</b> , 34, 336-47		31
357	How to value technological innovation: a proposal for determining relative clinical value. <b>2013</b> , 144, 5-8		5
356	Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. <b>2013</b> , 18, 325-37		76
355	Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. <b>2013</b> , 6, 724-31		61
354	Cost-effectiveness analysis: comparing single-level cervical disc replacement and single-level anterior cervical discectomy and fusion: clinical article. <b>2013</b> , 19, 546-54		66
353	Valuing postoperative recovery: validation of the SF-6D health-state utility. <b>2013</b> , 184, 108-14		21
352	Active surveillance, radiofrequency ablation, or cryoablation for the nonsurgical management of a small renal mass: a cost-utility analysis. <b>2013</b> , 20, 3675-84		20
351	The societal and economic value of rotator cuff repair. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2013</b> , 95, 1993-2000	5.6	237
350	Blood salvage produces higher total blood product costs in single-level lumbar spine surgery. <b>2013</b> , 38, 703-8		24
349	Patient time costs associated with sensor-augmented insulin pump therapy for type 1 diabetes: results from the STAR 3 randomized trial. <b>2013</b> , 33, 215-24		8
348	Societal and economic impact of anterior cruciate ligament tears. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2013</b> , 95, 1751-9	5.6	259
347	Outcomes Associated with the Use of Microprocessor-Controlled Prosthetic Knees among Individuals with Unilateral Transfemoral Limb Loss. <b>2013</b> , 25, 4-40		9

346	Cost-effectiveness of cervical cancer prevention. <b>2013</b> , 56, 55-64	7
345	Cost-effectiveness of the community-based management of severe acute malnutrition by community health workers in southern Bangladesh. <b>2013</b> , 28, 386-99	67
344	Overview of pharmacoeconomic modelling methods. <b>2013</b> , 75, 944-50	26
343	More donors or more delayed graft function? A cost-effectiveness analysis of DCD kidney transplantation. <b>2013</b> , 27, 289-96	23
342	Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma. <b>2013</b> , 119, 4299-307	53
341	A within-trial cost-effectiveness analysis of primary care referral to a commercial provider for weight loss treatment, relative to standard care--an international randomised controlled trial. <b>2013</b> , 37, 828-34	35
340	Cost effectiveness of intrathecal drug therapy in management of chronic nonmalignant pain. <b>2013</b> , 29, 138-45	18
339	Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials. <b>2013</b> , 25, 187-94	87
338	Automatic assessment of socioeconomic impact on cardiac rehabilitation. <b>2013</b> , 10, 5266-83	5
337	Cost implications to society of delaying childbearing. <b>2013</b> , 8, 9-14	1
336	Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. <b>2014</b> , 7, 341-50	23
335	Multisite artery disease: a common and challenging clinical condition calling for specific management. <b>2014</b> , 10, 395-407	1
334	The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. <b>2014</b> , 11 Suppl 2, S105-11	22
333	Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 3: assessment of economic outcome. <b>2014</b> , 21, 14-22	14
332	Evaluation of targeted mass cholera vaccination strategies in Bangladesh: a demonstration of a new cost-effectiveness calculator. <b>2014</b> , 91, 1181-1189	19
331	Cost-effectiveness of lumbar discectomy and single-level fusion for spondylolisthesis: experience with the NeuroPoint-SD registry. <b>2014</b> , 36, E3	32
330	Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma. <b>2014</b> , 28, 1084-91	15
329	Cost-effectiveness of follow-up of pulmonary nodules incidentally detected on cardiac computed tomographic angiography in patients with suspected coronary artery disease. <b>2014</b> , 130, 668-75	31

328	Should patients with ocular genetic disorders have genetic testing?. <b>2014</b> , 25, 359-65	5
327	The 5-year cost-effectiveness of anterior cervical discectomy and fusion and cervical disc replacement: a Markov analysis. <b>2014</b> , 39, 1924-33	40
326	Cost matters. <b>2014</b> , 123, 919-920	1
325	Economic analysis of revision amputation and replantation treatment of finger amputation injuries. <b>2014</b> , 133, 827-840	47
324	Tutorial on health economics and outcomes research in nutrition. <b>2014</b> , 38, 5S-16S	4
323	A comparison of the validity of two indirect utility instruments as measures of postoperative recovery. <b>2014</b> , 190, 79-86	16
322	Economic evaluation of access to musculoskeletal care: the case of waiting for total knee arthroplasty. <b>2014</b> , 15, 22	20
321	Cost effectiveness of duloxetine for osteoarthritis: a Quebec societal perspective. <b>2014</b> , 66, 702-8	7
320	Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia. <b>2014</b> , 32, 6941-6947	32
319	Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. <b>2014</b> , 40, 676-85	29
318	Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013. <b>2014</b> , 12, 391-408	47
317	Activity Begins in Childhood (ABC) - inspiring healthy active behaviour in preschoolers: study protocol for a cluster randomized controlled trial. <b>2014</b> , 15, 305	17
316	Cost-Effectiveness Analysis of Early Reconstruction Versus Rehabilitation and Delayed Reconstruction for Anterior Cruciate Ligament Tears. <b>2014</b> , 42, 1583-91	55
315	Research priorities for economic analyses of prevention: current issues and future directions. <b>2014</b> , 15, 789-98	25
314	Do changes in drug coverage policy point to an increased role for cost-effectiveness analysis in the USA?. <b>2014</b> , 32, 729-33	7
313	Can we build an efficient response to the prescription drug abuse epidemic? Assessing the cost effectiveness of universal prevention in the PROSPER trial. <b>2014</b> , 62, 71-7	29
312	Cost-effective studies in spine surgeries: a narrative review. <b>2014</b> , 14, 2748-62	15
311	The cost-effectiveness of boceprevir for hepatitis C. <b>2014</b> , 14, 319-34	1

310	Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis. <b>2014</b> , 121, 1855-62	36
309	Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial. <b>2014</b> , 15, 502	7
308	Constrained resources. 237-299	1
307	Cost-effectiveness of stereotactic radiosurgery with and without whole-brain radiotherapy for the treatment of newly diagnosed brain metastases. <b>2014</b> , 121 Suppl, 84-90	53
306	Valuing the Environment in Conservation Economics: Conceptual and Structural Barriers. <b>2014</b> , 19, 39	3
305	Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions. <b>2014</b> , 19, 425-36	37
304	A methodological analysis of the plastic surgery cost-utility literature using established guidelines. <b>2014</b> , 133, 584e-592e	3
303	Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. <i>Value in Health</i> , <b>2015</b> , 18, 1079-87	14
302	The Quality of Cost-Utility Analyses in Orthopedic Trauma. <b>2015</b> , 38, e673-80	21
301	The neglected topic: presentation of cost information in patient decision AIDS. <b>2015</b> , 35, 412-8	18
300	Are high drug prices for hematologic malignancies justified? A critical analysis. <b>2015</b> , 121, 3372-9	29
299	Cost-Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease. <b>2015</b> , 4,	7
298	A Cost-Utility Analysis of Lumbar Decompression With and Without Fusion for Degenerative Spine Disease in the Elderly. <b>2015</b> , 77 Suppl 4, S116-24	39
297	Economic Analysis of the Immunostimulant OM-85 for the Prevention of Paediatric Recurrent Upper Respiratory Tract Infections. <b>2015</b> , 2, GRHTA.5000200	4
296	Cost-consequence analysis of aprepitant compared to standard therapy (5-HT3 + corticosteroids) for the prevention of highly emetogenic chemotherapy-induced nausea and vomit. <b>2015</b> , 2, GRHTA.5000195	1
295	The Relative Impacts of Disease on Health Status and Capability Wellbeing: A Multi-Country Study. <b>2015</b> , 10, e0143590	43
294	Cost-effective analysis of unilateral vestibular weakness investigation. <b>2015</b> , 36, 277-81	13
293	Computed tomography screening for lung cancer in the National Lung Screening Trial: a cost-effectiveness analysis. <b>2015</b> , 30, 79-87	16

292	Updating Cost Effectiveness Analyses in Orthopedic Surgery: Resilience of the \$50,000 per QALY Threshold. <b>2015</b> , 30, 1118-20	40
291	Cost-Analyses Studies in Barrett's Esophagus: What Is Their Utility?. <b>2015</b> , 44, 425-38	5
290	Micronutrient program costs: sources of variations and noncomparabilities. <b>2015</b> , 36, 43-56	15
289	Relocation of remote dwellers living with hemodialysis: a time trade-off survey. <b>2015</b> , 30, 1767-73	7
288	Efficacy and cost-effectiveness of immediate surgery versus a wait-and-see strategy for sporadic nonfunctioning T1 pancreatic endocrine neoplasms. <b>2015</b> , 101, 25-34	8
287	Cost-effectiveness analyses in orthopaedic sports medicine: a systematic review. <b>2015</b> , 43, 1530-7	43
286	The evolution of the disability-adjusted life year (DALY). <b>2015</b> , 49, 10-15	31
285	Sex, race, and the adverse effects of social stigma vs. other quality of life factors among primary care patients with moderate to severe obesity. <b>2015</b> , 30, 229-35	25
284	Long-Term Outcomes of Adding HPV Vaccine to the Anal Intraepithelial Neoplasia Treatment Regimen in HIV-Positive Men Who Have Sex With Men. <b>2015</b> , 61, 1527-35	34
283	Health Aid Is Allocated Efficiently, But Not Optimally: Insights From A Review Of Cost-Effectiveness Studies. <b>2015</b> , 34, 1188-95	7
282	Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation. <b>2015</b> , 12, 1030-8	5
281	Towards integration of health economics into medical education and clinical practice in Saudi Arabia. <b>2015</b> , 37 Suppl 1, S56-60	6
280	A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection. <b>2015</b> , 13, 325-40	17
279	Randomized clinical trial of an integrated self-care intervention for persons with heart failure and diabetes: quality of life and physical functioning outcomes. <b>2015</b> , 21, 719-29	38
278	Validity of the EuroQol-5 dimensions as a measure of recovery after pulmonary resection. <b>2015</b> , 194, 281-8	8
277	An economic model assessing the value of microneedle patch delivery of the seasonal influenza vaccine. <b>2015</b> , 33, 4727-36	33
276	Cost considerations in implementing a screening and surveillance strategy for Barrett's oesophagus. <b>2015</b> , 29, 51-63	9
275	Surgical management for displaced pediatric proximal humeral fractures: a cost analysis. <b>2015</b> , 9, 55-64	7

274	Do chronic disease patients value generic health states differently from individuals with no chronic disease? A case of a multicultural Asian population. <b>2015</b> , 13, 8	9
273	Comparative effectiveness of home blood pressure telemonitoring (HBPTM) plus nurse case management versus HBPTM alone among Black and Hispanic stroke survivors: study protocol for a randomized controlled trial. <b>2015</b> , 16, 97	7
272	Determining the Ideal Strategy for Ventilator-associated Pneumonia Prevention. Cost-Benefit Analysis. <b>2015</b> , 192, 57-63	50
271	The Cost-Utility of Total Hip Arthroplasty: Earlier Intervention, Improved Economics. <b>2015</b> , 30, 945-9	32
270	Cost-Effectiveness in Minimally Invasive Urologic Surgery. <b>2015</b> , 239-250	0
269	A cost-utility analysis of the use of preoperative computed tomographic angiography in abdomen-based perforator flap breast reconstruction. <b>2015</b> , 135, 662e-669e	17
268	Cost-utility analyses in spine care: a qualitative and systematic review. <b>2015</b> , 40, 31-40	21
267	Predictive value of 3-month lumbar discectomy outcomes in the NeuroPoint-SD Registry. <b>2015</b> , 23, 459-66	12
266	Economic analysis of universal active surveillance screening for methicillin-resistant <i>Staphylococcus aureus</i> : perspective matters. <b>2015</b> , 36, 14-6	4
265	Self-management support intervention to control cancer pain in the outpatient setting: a randomized controlled trial study protocol. <b>2015</b> , 15, 416	11
264	Dollars and sense. <b>2015</b> , 43, 1313-5	1
263	Cost-utility analysis of the use of prophylactic mesh augmentation compared with primary fascial suture repair in patients at high risk for incisional hernia. <b>2015</b> , 158, 700-11	33
262	Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort study. <b>2015</b> , 13, 193-205	10
261	Cost-effectiveness analysis of the diagnosis of meniscus tears. <b>2015</b> , 43, 128-37	28
260	Burden of Disease Study and Priority Setting in Korea: an Ethical Perspective. <b>2016</b> , 31 Suppl 2, S108-S113	1
259	Accommodation Consumers and Providers' Attitudes, Behaviours and Practices for Sustainability: A Systematic Review. <b>2016</b> , 8, 625	19
258	Medical costs and quality-adjusted life years associated with smoking: a systematic review. <b>2016</b> , 16, 646	13
257	Cost-effective Decisions in Detecting Silent Common Bile Duct Gallstones During Laparoscopic Cholecystectomy. <b>2016</b> , 263, 1164-72	11

256	A Cost-Utility Assessment of Mesh Selection in Clean-Contaminated Ventral Hernia Repair. <b>2016</b> , 137, 647-659	41
255	Chronic rhinosinusitis: Epidemiology and burden of disease. <b>2016</b> , 30, 134-9	173
254	Probabilistic measures of cost-effectiveness. <b>2016</b> , 35, 3976-86	0
253	Health utility values for patients with recurrent acute rhinosinusitis undergoing endoscopic sinus surgery: a nested case control study. <b>2016</b> , 6, 1182-1187	9
252	Cost-effectiveness of preventive case management for parents with a mental illness: a randomized controlled trial from three economic perspectives. <b>2016</b> , 16, 228	11
251	Guidelines for reporting health economic research. <b>2016</b> , 98-B, 147-51	9
250	Value within otolaryngology: Assessment of the cost-utility analysis literature. <b>2016</b> , 2, 28-37	5
249	Overtreatment and Cost-Effectiveness of the See-and-Treat Strategy for Managing Cervical Precancer. <b>2016</b> , 25, 807-14	7
248	A cost-effectiveness analysis of two different antimicrobial stewardship programs. <b>2016</b> , 20, 255-61	17
247	Establishing Cost-Effective Allocation of Proton Therapy for Breast Irradiation. <b>2016</b> , 95, 11-18	30
246	Effect of obesity on cost per quality-adjusted life years gained following anterior cervical discectomy and fusion in elective degenerative pathology. <b>2016</b> , 16, 1342-1350	22
245	Weight management for adolescents with intellectual and developmental disabilities: Rationale and design for an 18month randomized trial. <b>2016</b> , 51, 88-95	7
244	Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis. <b>2016</b> , 16, 344	10
243	Cost and cost threshold analyses for 12 innovative US HIV linkage and retention in care programs. <b>2016</b> , 28, 1199-204	16
242	Improving data collection processes for routine evaluation of treatment cost-effectiveness. <b>2016</b> , 45, 45-52	5
241	The Economic Impact of Acetabular Labral Tears: A Cost-effectiveness Analysis Comparing Hip Arthroscopic Surgery and Structured Rehabilitation Alone in Patients Without Osteoarthritis. <b>2016</b> , 44, 1771-80	17
240	Adherence With Therapeutic Regimens: Behavioral and Pharmacoeconomic Perspectives. <b>2016</b> , 29, 138-43	5
239	Reconceptualising public acceptability: A study of the ways people respond to policies aimed to reduce alcohol consumption. <b>2016</b> , 20, 203-19	11

238	Costs in Comparative Effectiveness Research. <b>2016</b> , 205-216		
237	A high-risk group of pregnant women with elevated levels of conflict-related trauma, intimate partner violence, symptoms of depression and other forms of mental distress in post-conflict Timor-Leste. <b>2016</b> , 6, e725		21
236	Cost of diabetic eye, renal and foot complications: a methodological review. <i>European Journal of Health Economics</i> , <b>2017</b> , 18, 293-312	3.6	12
235	Reducing the burden of suffering from eating disorders: Unmet treatment needs, cost of illness, and the quest for cost-effectiveness. <b>2017</b> , 88, 49-64		72
234	Cost-Effectiveness of Watchful Waiting in Acute Otitis Media. <b>2017</b> , 139,		13
233	Cost-effectiveness of mediastinal lymph node staging in non-small cell lung cancer. <b>2017</b> , 153, 1567-1578		17
232	Value in cardiovascular care. <b>2017</b> , 103, 1238-1243		14
231	The Cost-Effectiveness of Dual Mobility Implants for Primary Total Hip Arthroplasty: A Computer-Based Cost-Utility Model. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2017</b> , 99, 768-777	5.6	38
230	Economic Decision Model for First-Time Traumatic Patellar Dislocations in Adolescents. <b>2017</b> , 45, 2267-2275		18
229	A dynamic default revision mechanism for speculative computation. <b>2017</b> , 31, 656-695		3
228	The economic burden of physical inactivity: a systematic review and critical appraisal. <b>2017</b> , 51, 1392-1409		61
227	Comparative cost-benefit analysis of tele-homecare for community-dwelling elderly in Japan: Non-Government versus Government Supported Funding Models. <b>2017</b> , 104, 1-9		4
226	Laparoscopic Versus Open Cholecystectomy: A Cost-Effectiveness Analysis at Rwanda Military Hospital. <b>2017</b> , 41, 1225-1233		12
225	Cost-effectiveness of MR Imaging-guided Strategies for Detection of Prostate Cancer in Biopsy-Naive Men. <b>2017</b> , 285, 157-166		51
224	Defining Value: The Need for a Longer, Broader View. <b>2017</b> , 35, 669-672		4
223	Bending the Cost Curve-Establishing Value in Spine Surgery. <b>2017</b> , 80, S61-S69		19
222	Incremental cost-effectiveness ratio and net monetary benefit: Current use in pharmacoeconomics and future perspectives. <b>2017</b> , 43, e36		16
221	The Cost and Threshold Analysis of Retention in Care (RiC): A Multi-Site National HIV Care Program. <b>2017</b> , 21, 643-649		5



220	Cost-effectiveness Analysis of Hip Arthroscopic Surgery and Structured Rehabilitation Alone in Individuals With Hip Labral Tears: Response. <b>2017</b> , 45, NP2-NP4	1
219	Cost-effectiveness Analysis Appraisal and Application: An Emergency Medicine Perspective. <b>2017</b> , 24, 754-768	19
218	OMERACT Quality-adjusted Life-years (QALY) Working Group: Do Current QALY Measures Capture What Matters to Patients?. <b>2017</b> , 44, 1899-1903	8
217	Restrictive versus liberal red blood cell transfusion strategy after hip surgery: a decision model analysis of healthcare costs. <b>2017</b> , 57, 357-366	9
216	Digital technology in fixed implant prosthodontics. <b>2017</b> , 73, 178-192	88
215	Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement. <b>2017</b> , 196, e15-e29	57
214	Cost-Effectiveness of a Clinical Childhood Obesity Intervention. <b>2017</b> , 140,	12
213	Evaluating the Costs of IR in Health Care Delivery: Proceedings from a Society of Interventional Radiology Research Consensus Panel. <b>2017</b> , 28, 1475-1486	6
212	Economics of Preventing, Screening, and Treating Oral Cancers. <b>2017</b> , 283-297	1
211	The Health Economics of the spinal cord injury or disease among veterans of war: A systematic review. <b>2017</b> , 40, 649-664	11
210	Effectiveness and Cost-Effectiveness of Endoscopic Screening and Surveillance. <b>2017</b> , 27, 397-421	13
209	Comparing effectiveness and outcomes in asthma and cystic fibrosis. <b>2017</b> , 24, 24-28	
208	Predicting Productivity Losses from Health-Related Quality of Life Using Patient Data. <b>2017</b> , 15, 597-614	3
207	Treatment of Massive Irreparable Rotator Cuff Tears: A Cost-effectiveness Analysis. <b>2017</b> , 40, e65-e76	19
206	International lessons in new methods for grading and integrating cost effectiveness evidence into clinical practice guidelines. <b>2017</b> , 15, 1	15
205	Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies. <b>2017</b> , 35, 76-85	14
204	Suture Button Fixation Versus Syndesmotic Screws in Supination-External Rotation Type 4 Injuries: A Cost-Effectiveness Analysis. <b>2017</b> , 45, 210-217	39
203	Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer. <b>2017</b> , 37, 94-103	11

202	Advanced Imaging Adds Little Value in the Diagnosis of Femoroacetabular Impingement Syndrome. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2017</b> , 99, e133	5.6	11
201	Adding Azithromycin to Cephalosporin for Cesarean Delivery Infection Prophylaxis: A Cost-Effectiveness Analysis. <b>2017</b> , 130, 1279-1284		10
200	Using the Value Equation Improving Pediatric Healthcare in Publicly Funded Healthcare Systems. <b>2017</b> , 3, 353-361		
199	Health utilities for chronic low back pain. <b>2017</b> , 12, 28		4
198	Worldwide Economic Costs and Societal Burden of Dementia. <b>2018</b> , 3-13		2
197	Cost Analysis of Single-Dose Hepatitis B Revaccination Among Infants Born to Hepatitis B Surface Antigen-Positive Mothers and Not Responding to the Initial Vaccine Series. <b>2018</b> , 133, 338-346		2
196	Cost-effectiveness of HIV screening in high-income countries: A systematic review. <b>2018</b> , 122, 533-547		19
195	The Seven-Year Cost-Effectiveness of Anterior Cervical Discectomy and Fusion Versus Cervical Disc Arthroplasty: A Markov Analysis. <b>2018</b> , 43, 1543-1551		20
194	Cost-effectiveness of vaccination against cytomegalovirus (CMV) in adolescent girls to prevent infections in pregnant women living in France. <b>2018</b> , 36, 1285-1296		4
193	The Economic Burden of Asthma in the United States, 2008-2013. <b>2018</b> , 15, 348-356		339
192	The underreporting of cost perspective in cost-analysis research: A systematic review of the plastic surgery literature. <b>2018</b> , 71, 366-376		9
191	The economic advantage of allergen immunotherapy over drug treatment in respiratory allergy. <b>2018</b> , 21, 553-555		5
190	Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model. <b>2018</b> , 18, 464		11
189	The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective. <b>2018</b> , 6, 15		13
188	Effects of Arthroscopy for Femoroacetabular Impingement Syndrome on Quality of Life and Economic Outcomes. <b>2018</b> , 46, 1205-1213		28
187	Cost-Effectiveness in Adult Spinal Deformity Surgery. <b>2018</b> , 83, 597-601		11
186	Using continuous quantitative capnography for emergency department procedural sedation: a systematic review and cost-effectiveness analysis. <b>2018</b> , 13, 75-85		2
185	HIV screening in pregnant women: A systematic review of cost-effectiveness studies. <b>2018</b> , 33, 31-50		11

184	A systematic review of the cost and economic outcomes of home enteral nutrition. <b>2018</b> , 37, 429-442		19
183	Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial. <b>2018</b> , 27, 656-665		8
182	Factors influencing direct clinical costs of outpatient arthroscopic rotator cuff repair surgery. <b>2018</b> , 27, 237-241		20
181	The effectiveness of psychological interventions on self-care, psychological and health outcomes in patients with chronic heart failure-A systematic review and meta-analysis. <b>2018</b> , 78, 16-25		32
180	Les principes de l'analyse médico-économique appliqués au cancer du poumon. <b>2018</b> , 10, 198-206		
179	Evaluating meniscus allograft transplant using a cost-effectiveness threshold analysis. <b>2018</b> , 25, 1171-1180		9
178	Cost-Effectiveness of Surgical and Nonsurgical Treatments for Unicompartmental Knee Arthritis: A Markov Model. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2018</b> , 100, 1653-1660	5.6	14
177	Remote delivery of weight management for adults with intellectual and developmental disabilities: Rationale and design for a 24 month randomized trial. <b>2018</b> , 73, 16-26		1
176	A Guide to the Economics of Hepatitis C Virus Cure in 2017. <b>2018</b> , 32, 447-459		3
175	Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?. <b>2018</b> , 63, 2094-2104		19
174	Assessment of components included in published societal perspective or QALY outcome economic analyses for antiepileptic drug treatment in chronic epilepsy. <b>2018</b> , 18, 487-503		1
173	Cost effectiveness and clinical efficacy of patent foramen ovale closure as compared to medical therapy in cryptogenic stroke patients: A detailed cost analysis and meta-analysis of randomized controlled trials. <b>2018</b> , 273, 74-79		5
172	Cost-effectiveness analysis of a school-based dental caries prevention program using fluoridated milk in Bangkok, Thailand. <b>2018</b> , 18, 24		6
171	Economic evaluation of HIV pre-exposure prophylaxis strategies: protocol for a methodological systematic review and quantitative synthesis. <b>2018</b> , 7, 47		
170	Perceptions of Existing Wearable Robotic Devices for Upper Extremity and Suggestions for Their Development: Findings From Therapists and People With Stroke. <b>2018</b> , 5, e12		13
169	Methods of Melanoma Detection. <b>2018</b> , 39-85		
168	Cost-utility analysis of genetic polymorphism universal screening in colorectal cancer prevention by detection of high-risk individuals. <b>2019</b> , 51, 1731-1737		2
167	Convergent validity of the EQ-5D-3L in a randomized-controlled trial of the Housing First model. <b>2019</b> , 19, 482		2

166	Assessing the cost-effectiveness of interventions within a humanitarian organisation. <b>2019</b> , 43, 575-590	5
165	A Cost and Cost-Threshold Analysis of Implementation of an Evidence-Based Intervention for HIV-Serodiscordant Couples. <b>2019</b> , 23, 2486-2489	
164	Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance. <b>2019</b> , 22, 1202-1209	12
163	Economic value and cost-effectiveness of biventricular versus right ventricular pacing: results from the BLOCK-HF study. <b>2019</b> , 22, 1088-1095	5
162	The cost-effectiveness of requiring universal vs contextual self-injectable epinephrine autoinjector for allergen immunotherapy. <b>2019</b> , 123, 582-589	9
161	The impact of contracts on outsourcing computed tomography examinations from a Swedish public university hospital to a private radiology unit. <b>2019</b> , 25, 148-154	3
160	Cardiac CT: Comparative Cost-Effectiveness. <b>2019</b> , 673-679	
159	A Comparative Health Utility Value Analysis of Outcomes for Patients Following Septorhinoplasty With Previous Nasal Surgery. <b>2019</b> , 21, 402-406	5
158	Adherence to the iDSI reference case among published cost-per-DALY averted studies. <b>2019</b> , 14, e0205633	21
157	Disparities in Statin Use in New York City: Implications for Health Reform. <b>2019</b> , 6, 463-471	
156	A Cost-utility Analysis of Percutaneous Endoscopic Lumbar Discectomy for L5-S1 Lumbar Disc Herniation: Transforaminal versus Interlaminar. <b>2019</b> , 44, 563-570	14
155	The costs of negative affect attributable to alcohol consumption in later life: A within-between random longitudinal econometric model using UK Biobank. <b>2019</b> , 14, e0211357	
154	Cost-utility analysis of colonoscopy or faecal immunochemical test for population-based organised colorectal cancer screening. <b>2019</b> , 7, 105-113	8
153	Is quality affordable for community health systems? Costs of integrating quality improvement into close-to-community health programmes in five low-income and middle-income countries. <b>2019</b> , 4, e001390	3
152	Cost-Effectiveness Analysis for Cardiovascular Magnetic Resonance Imaging. <b>2019</b> , 568-573.e1	0
151	The Economic Impact of Flexor Tendon Lacerations of the Hand in the United States. <i>Annals of Plastic Surgery</i> , <b>2019</b> , 83, 419-423	1.7 4
150	Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia. <b>2019</b> , 25, 418-427	6
149	Patient-Level Value Analysis: An Innovative Approach to Optimize Care Delivery. <b>2019</b> , 33 Suppl 7, S49-S52	5

148	Use of Checklists in Reviews of Health Economic Evaluations, 2010 to 2018. <i>Value in Health</i> , <b>2019</b> , 22, 377-382	3.3	32
147	Health Care Costs and Cost-effectiveness in Laryngotracheal Stenosis. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2019</b> , 160, 679-686	5.5	10
146	Cost-Effectiveness Analysis: An Overview of Key Concepts, Recommendations, Controversies, and Pitfalls. <b>2019</b> , 26, 534-541		6
145	Economic evaluation in implementation science: Making the business case for implementation strategies. <b>2020</b> , 283, 112433		41
144	Using Cost-Effectiveness Analysis in Mixed Methods Research: An Evaluation of an Integrated Care Program for Frequently Hospitalized Older Adults in Singapore. <b>2020</b> , 14, 227-247		1
143	Do Optimization Models for Humanitarian Operations Need a Paradigm Shift?. <b>2020</b> , 29, 55-61		14
142	Cost-effectiveness of Operative Versus Non-operative Management of Acute Achilles Tendon Ruptures. <b>2020</b> , 16, 39-45		5
141	Is There Something Else Beyond Cost-Effectiveness Analysis for Public Health Decision Making?. <b>2020</b> , 23, 1-5		1
140	Cost-Effectiveness Analysis in Pediatric Imaging: The Evidence (or Lack Thereof) Thus Far. <b>2020</b> , 17, 452-461		4
139	Population-Based Health Utility Assessment of Migraine Headache Symptoms before and after Surgical Intervention. <b>2020</b> , 145, 210-217		0
138	Biomarkers in Lung Cancer. <b>2020</b> , 41, 115-127		19
137	First trimester fasting plasma glucose screen in advanced maternal age women: a cost-effectiveness analysis. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2020</b> , 1-7	2	0
136	Weight management for adults with mobility related disabilities: Rationale and design for an 18-month randomized trial. <b>2020</b> , 96, 106098		
135	Cost-effectiveness analysis of cinacalcet for haemodialysis patients with moderate-to-severe secondary hyperparathyroidism in China: evaluation based on the EVOLVE trial. <b>2020</b> , 10, e034123		
134	Lifetime survival and medical costs of lung cancer: a semi-parametric estimation from South Korea. <b>2020</b> , 20, 846		2
133	Cost-utility analysis of extensile lateral approach versus sinus tarsi approach in Sanders type II/III calcaneus fractures. <b>2020</b> , 15, 430		2
132	Cost of Increasing Years-of-Life-Gained (YLG) Using Fecal Immunochemical Testing as a Population-Level Screening Model in a Rural Appalachian Population. <b>2021</b> , 37, 576-584		0
131	Clinical utility of genomic sequencing: a measurement toolkit. <b>2020</b> , 5, 56		14

130	Cost and logistics implications of a nationwide survey of schistosomiasis and other intestinal helminthiasis in Sudan: Key activities and cost components. <b>2020</b> , 15, e0226586	2
129	International phase 1 study protocol to develop a health state classification system for a preference-based measure for women with breast cancer: the BREAST-Q Utility module. <b>2020</b> , 10, e034451	3
128	Ethical decision-making for children with neuromuscular disorders in the COVID-19 crisis. <b>2020</b> , 95, 260-265	5
127	Cost-effectiveness analysis of proton beam therapy for treatment decision making in paranasal sinus and nasal cavity cancers in China. <b>2020</b> , 20, 599	7
126	What Is the Appropriate Price for Platelet-Rich Plasma Injections for Knee Osteoarthritis? A Cost-Effectiveness Analysis Based on Evidence From Level I Randomized Controlled Trials. <b>2020</b> , 36, 1983-1991.e1	9
125	The Use of Intraoperative Neurophysiological Monitoring in Spine Surgery. <b>2020</b> , 10, 104S-114S	35
124	Time-Driven Activity-Based Costing to Model Cost Utility of Enhanced Recovery after Surgery Pathways in Microvascular Breast Reconstruction. <b>2020</b> , 230, 784-794.e3	12
123	Health utility and quality of life in pediatric liver transplant recipients. <b>2020</b> , 24, e13720	2
122	Cost-effectiveness of second curettage for treatment of low-risk non-metastatic gestational trophoblastic neoplasia. <b>2020</b> , 157, 711-715	1
121	Healthy Eating and Physical Activity Interventions in Faith-Based Settings: A Systematic Review Using the Reach, Effectiveness/Efficacy, Adoption, Implementation, Maintenance Framework. <b>2021</b> , 60, 127-135	5
120	Italian cost analysis of free flap surgery in head and neck reconstruction using the activity-based costing (ABC). <b>2021</b> , 74, 1279-1285	0
119	Bilateral Deep Brain Stimulation is the Procedure to Beat for Advanced Parkinson Disease: A Meta-Analytic, Cost-Effective Threshold Analysis for Focused Ultrasound. <b>2021</b> , 88, 487-496	4
118	Comparing the Preferences of Patients and the General Public for Treatment Outcomes in Type 2 Diabetes Mellitus. <b>2021</b> , 14, 89-100	3
117	Cost-Effectiveness of HRSA's Ryan White HIV/AIDS Program?. <b>2021</b> , 86, 174-181	2
116	Development of a Mathematical Model to Estimate the Cost-Effectiveness of HRSA's Ryan White HIV/AIDS Program. <b>2021</b> , 86, 164-173	2
115	Comparisons of initial outcomes and cost-effectiveness after total ankle arthroplasty versus bipolar osteochondral allograft transplantation in the ankle: a retrospective cohort study. <b>2021</b> , 32, 232-236	
114	Value of Anti-Vascular Endothelial Growth Factor Gene Therapy for Neovascular Age-Related Macular Degeneration. <b>2021</b> , 5, 357-364	
113	Cost-Effectiveness Analysis of Transcatheter Arterial Embolization Techniques for the Treatment of Gastrointestinal Bleeding in the United States. <i>Value in Health</i> , <b>2021</b> , 24, 477-485	3-3 1

112	Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. <i>European Journal of Health Economics</i> , <b>2021</b> , 22, 723-733	3.6	2
111	Cost Comparison of Botulinum Toxin Injections Versus Surgical Treatment in Pediatric Patients With Cerebral Palsy: A Markov Model. <b>2021</b> , 46, 359-367		0
110	Differentiated Thyroid Cancer: A Health Economic Review. <b>2021</b> , 13,		1
109	Current Orthopaedic Health Economic Literature: Quality Is High but Ethical and Societal Perspectives Are Lacking. <b>2021</b> , 37, 2000-2008		0
108	Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett's Esophagus Screening. <b>2021</b> , 116, 1620-1631		4
107	Infections associated with cardiac electronic implantable devices: economic perspectives and impact of the TYRX <sup>®</sup> antibacterial envelope. <b>2021</b> , 23, iv33-iv44		4
106	A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France. <b>2021</b> , 16, e0252130		5
105	Cost-Effectiveness Analysis Between Sacral Neuromodulation and OnabotulinumtoxinA for the Treatment of Refractory Overactive Bladder in Women: A Systematic Review. <b>2021</b> , 27, 481-487		
104	Short- and Long-term Health Care Resource Utilization and Costs Following Intracerebral Hemorrhage. <b>2021</b> , 97, e608-e618		0
103	Cost-Effectiveness Comparison of Delivery Modalities for a Dissonance-Based Eating Disorder Prevention Program over 4-Year Follow-Up. <b>2021</b> , 22, 1086-1095		1
102	The Economic Impact of Extensor Tendon Lacerations of the Hand in the United States. <i>Annals of Plastic Surgery</i> , <b>2021</b> ,	1.7	
101	Endovascular Revascularization Plus Supervised Exercise Versus Supervised Exercise Only for Intermittent Claudication: A Cost-Effectiveness Analysis. <b>2021</b> , 14, e010703		
100	A framework to support the integration of priority setting in the preparedness, alert, control and evaluation stages of a disease pandemic. <b>2021</b> , 1-13		0
99	Indirect costs associated with out-of-country referral for proton therapy: a survey of adult and pediatric patients in Alberta, Canada. <b>2021</b> , 21, 683		0
98	Optimizing oropharyngeal cancer management by using proton beam therapy: trends of cost-effectiveness. <b>2021</b> , 21, 944		0
97	Measurement of value in rotator cuff repair: patient-level value analysis for the 1-year episode of care. <b>2022</b> , 31, 72-80		1
96	Establishing Cost-Effective Allocation of Proton Therapy for Patients With Mediastinal Hodgkin Lymphoma. <b>2021</b> ,		0
95	Adjunct diagnostic strategies in improving diagnostic yields in image-guided biopsies of musculoskeletal neoplasms-A cost-effectiveness analysis. <b>2021</b> , 124, 1499-1507		0

94	Assessing quality-adjusted years of life lost associated with exclusive cigarette smoking and smokeless tobacco use. <b>2021</b> , 150, 106707		1
93	'Value' of advance care plans: health economics revisited. <b>2021</b> ,		
92	A Framework that Considers the Impacts of Time, Cost, and Uncertainty in the Determination of the Cost Effectiveness of Toxicity-Testing Methodologies. <b>2021</b> ,		0
91	Economic Evaluations of Child Nutrition Interventions in Low- and Middle-Income Countries: Systematic Review and Quality Appraisal. <b>2021</b> ,		1
90	What Are Values, Utilities, and Preferences? A Clarification in the Context of Decision Making in Health Care, and an Exploration of Measurement Issues. <b>2016</b> , 3-13		3
89	Economics of Hematopoietic Growth Factors. <b>2004</b> , 409-443		5
88	The Question of Value. <b>2016</b> , 63-81		2
87	Long-term Economic Consequences of Surviving Intensive Care. <b>2003</b> , 73-83		0
86	Muscle strength is related to mental and physical quality of life in the oldest old. <b>2020</b> , 89, 104109		6
85	Methodologic principles of cost analyses in the nursing, medical, and health services literature, 1990-1996. <b>1999</b> , 48, 94-104		24
84	Pharmaceuticals--cost or investment? An employer's perspective. <b>2000</b> , 42, 338-51		20
83	Economic evaluation of cardiac rehabilitation: a systematic review. <b>2005</b> , 12, 513-520		48
82	The economic burden of prostate cancer - a Swedish prevalence-based register study. <b>2020</b> , 20, 448		9
81	Cost-Effectiveness of Increasing Influenza Vaccination Coverage in Adults with Type 2 Diabetes in Turkey. <b>2016</b> , 11, e0157657		8
80	The best infertility treatment for vasectomized men: assisted reproduction or vasectomy reversal?. <b>2004</b> , 59, 312-5		9
79	Managed Care. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>1997</b> , 79, 125-136	5.6	14
78	Economic evaluation in orthopaedics. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2003</b> , 85, 129-42	5.6	57
77	An Economic Analysis of the Timing of Microsurgical Reconstruction in Brachial Plexus Birth Palsy. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2007</b> , 89, 970-978	5.6	7



76	Seeking Novel Value Creation Paradigms to Sustain Future Growth: The Case of Public Healthcare Policies. <i>SSRN Electronic Journal</i> ,	1	1
75	[Not Available]. <i>Open Cardiovascular Medicine Journal</i> , <b>2009</b> , 3, 15-20	0.7	2
74	Predicting Therapy Success and Costs for Personalized Treatment Recommendations Using Baseline Characteristics: Data-Driven Analysis. <i>Journal of Medical Internet Research</i> , <b>2018</b> , 20, e10275	7.6	17
73	The Stepped Care Intervention to Suppress Viral Load in Youth Living With HIV: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , <b>2019</b> , 8, e10791	2	17
72	From eHealth technologies to interventions. <i>Journal of Medical Internet Research</i> , <b>2012</b> , 14, e93	7.6	7
71	Mobile App for Treatment of Stress Urinary Incontinence: A Cost-Effectiveness Analysis. <i>Journal of Medical Internet Research</i> , <b>2017</b> , 19, e154	7.6	27
70	Multisite implementation of trained volunteer doula support for disadvantaged childbearing women: a mixed-methods evaluation. <i>Health Services and Delivery Research</i> , <b>2015</b> , 3, 1-332	1.5	14
69	The Benefits of Big Data Analytics in the Healthcare Sector. <i>Advances in Bioinformatics and Biomedical Engineering Book Series</i> , <b>2015</b> , 406-439	0.4	2
68	The Benefits of Big Data Analytics in the Healthcare Sector. <b>2016</b> , 842-875		1
67	Techniques for Determining the Treatment Costs of Cervical Cancer: A Systematic Review. <i>Open Journal of Obstetrics and Gynecology</i> , <b>2019</b> , 09, 117-128	0.1	1
66	Towards Resilient Health Systems in Sub-Saharan Africa: A Systematic Review of the English Language Literature on Health Workforce, Surveillance, and Health Governance Issues for Health Systems Strengthening. <i>Annals of Global Health</i> , <b>2019</b> , 85,	3.3	7
65	Sirolimus and non-melanoma skin cancer prevention after kidney transplantation: a meta-analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2012</b> , 13, 4335-9	1.7	18
64	The quality of reporting in published cost-utility analyses, 1976-1997. <i>Annals of Internal Medicine</i> , <b>2000</b> , 132, 964-72	8	141
63	Cost-effectiveness of Single vs Double Debridement and Implant Retention for Acute Periprosthetic Joint Infections in Total Knee Arthroplasty: A Markov Model. <i>Arthroplasty Today</i> , <b>2021</b> , 11, 187-195	2	1
62	Lisfranc injuries: fix or fuse? : a systematic review and meta-analysis of current literature presenting outcome after surgical treatment for Lisfranc injuries. <i>Bone &amp; Joint Open</i> , <b>2021</b> , 2, 842-849	2.8	2
61	Surgeons and Health Services Research. <b>2001</b> , 1393-1404		
60	Hypothesis Generation: Asking the Right Question, Getting the Correct Answer. <b>2002</b> , 167-184		
59	Cost-Effectiveness of Alternatives to Allogeneic Blood Transfusion; Reviewing the Available Evidence. <b>2002</b> , 131-142		

- 58 Disease management in chronic medical conditions. **2003**, 457-470
- 57 Assessment of Outcomes in Head and Neck Cancer. **2003**, 433-444
- 56 Risikoabschätzung, Leistungserfassung, Qualitätsmanagement. **2004**, 83-92
- 55 What Affects the Quality of Economic Analysis for Life-Saving Investments?. *SSRN Electronic Journal* , 1
- 54 COST-UTILITY ANALYSES IN ORTHOPAEDIC SURGERY. *Journal of Bone and Joint Surgery - Series A*, **2005**, 87, 1253-1259 5.6 1
- 53 Chapter 7. **2005**, 76-85
- 52 A Health Capability Account of Equitable and Efficient Health Financing and Insurance. **2009**, 159-171
- 51 Gesundheitsökonomische Bewertungen. **2010**, 557-573
- 50 Cost-Effectiveness of Myocardial Perfusion Single-Photon Emission Computed Tomography. **2010**, 400-412
- 49 Outcomes Research. **2010**, 52-58
- 48 3 Cost consequences analysis. **2011**, 210-212
- 47 Cost-Effectiveness of Screening for and Early Diagnosis of Breast and Gynecological Cancers in Low-Income Countries. **2013**, 201-213
- 46 Economic Evaluation of Health Care for Chronic Diseases. **1998**, 149-154
- 45 Discourse on Method: Measuring the Value of New Therapies in Intensive Care. *Yearbook of Intensive Care and Emergency Medicine*, **1998**, 263-279
- 44 The Role of Cost-Effectiveness Analysis in Defining Transfusion Medicine Policy. **1999**, 47-57
- 43 Test Utilization and Clinical Relevance. 876-889
- 42 Principles of health economics and application to rheumatic disorders. **2015**, 20-26
- 41 Costs in Comparative Effectiveness Research. **2015**, 1-13

40 Efficiency and Variance Reduction. **2015**, 256-273

39 Cost effectiveness of robot-assisted urologic oncological surgery in the United States. *World Journal of Clinical Urology*, **2016**, 5, 24 0

38 Economic Evaluations. **2017**, 409-426

37 Afterword. **2017**, 325-326

36 The Role of Predictive Markers in Outcome and Value of Anticancer Drugs in Non-small Cell Lung Cancer. *Journal of Exploratory Research in Pharmacology*, **2018**, 3, 102-104 0.4

35 Adherence to the iDSI reference case among published cost-per-DALY averted studies.

34 Performance Measurement in Social Enterprises. *Advances in Business Strategy and Competitive Advantage Book Series*, **2019**, 205-231 0.3

33 Cost implications of a nationwide survey of schistosomiasis and other intestinal helminthiasis in Sudan.

32 Medications safety pharmacoeconomics-related issues. **2020**, 187-195

31 Quality of life evaluation of patients after radical treatment of prostate cancer. *Proceedings of the National Academy of Sciences of Belarus, Medical Series*, **2020**, 17, 275-286 0.2

30 Economic evaluation of low-dose SKA cytokines in patients with rheumatoid arthritis in maintaining low disease activity or remission. *AboutOpen*, **2020**, 7, 67-73 0.3

29 Economic Evaluation of CAM Use. *Advances in Medical Diagnosis, Treatment, and Care*, 232-271 0.2

28 Improving Child and Adolescent Mental Health in Africa: A Review of the Economic Evidence. **2022**, 41-65

27 Endovascular stent grafting and open surgical replacement for chronic thoracic aortic aneurysms: a systematic review and prospective cohort study.. *Health Technology Assessment*, **2022**, 26, 1-166 4.4

26 Clinical Response and Hospital Costs of Therapeutic Drug Monitoring for Vancomycin in Elderly Patients.. *Journal of Personalized Medicine*, **2022**, 12, 3.6

25 Can responsive deep brain stimulation be a cost-effective treatment for severe obesity?. *Obesity*, **2022**, 30, 338-346 8 0

24 Cost-effectiveness of Canal Wall-Up vs Canal Wall-Down Mastoidectomy: A Modeling Study.. *Otolaryngology - Head and Neck Surgery*, **2022**, 1945998221076051 5.5

23 Economic impact of selective use of contrast for routine follow-up MRI of patients with multiple sclerosis.. *Journal of Neuroimaging*, **2022**, 2.8 0

22	Establishing a method to estimate the effect of antimyopia management options on lifetime cost of myopia.. <i>British Journal of Ophthalmology</i> , <b>2022</b> ,	5.5	0
21	A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots.. <i>European Journal of Health Economics</i> , <b>2022</b> , 1	3.6	0
20	A cost-benefit analysis framework for preventive health interventions to aid decision-making in Australian governments.. <i>Health Research Policy and Systems</i> , <b>2021</b> , 19, 147	3.7	1
19	Delivery timing in dichorionic diamniotic twin pregnancies complicated by preeclampsia: a decision analysis.. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2022</b> , 1-6	2	0
18	The economics of cancer-related symptoms: valuing supportive-care interventions. 259-267		
17	Evaluating the Inaccuracy of the National Surgical Quality Improvement Project Surgical Risk Calculator in Plastic Surgery: A Meta-analysis of Short-Term Predicted Complications.. <i>Annals of Plastic Surgery</i> , <b>2022</b> , 88, S219-S223	1.7	
16	Overview of Health Economics. <b>2022</b> , 1-18		
15	A Telehealth and Telepsychiatry Economic Cost Analysis Framework: Scoping Review. <i>Telemedicine Journal and E-Health</i> ,	5.9	2
14	No Time to Waste: An Appraisal of Value at the End of Life. <i>Value in Health</i> , <b>2022</b> ,	3.3	
13	COST-BENEFIT ANALYSIS FOR ALLERGEN IMMUNOTHERAPY. <i>Radiologic Clinics of North America</i> , <b>2000</b> , 20, 593-607	2.3	
12	Copyright Page. <b>2009</b> , iv-iv		
11	Dedication. <b>2009</b> , v-vi		
10	The Cost Utility of Virtual Surgical Planning and Computer-Assisted Design/Computer-Assisted Manufacturing in Mandible Reconstruction Using the Free Fibula Osteocutaneous Flap.		
9	Willingness to Pay and Time Trade-off in Thai Patients with Port-Wine Stains. Volume 14, 635-642		0
8	price-variation-among-registered-brands-of-anti-cancer-medicines-available-in-pakistan. <b>2022</b> , 8, 42-56		0
7	Die gesundheitsökonomische Evaluation der GLICEMIA 2.0-Studie als Beispiel für eine komplexe Intervention.		0
6	Data Use in Public Health. <b>2022</b> , 181-199		0
5	Navigated intramedullary nailing for patients with intertrochanteric hip fractures is cost-effective at high-volume hospitals in mainland China: A markov decision analysis. 9,		0

- 4 Cost-analysis of real time RT-PCR test performed for COVID-19 diagnosis at India's national reference laboratory during the early stages of pandemic mitigation. **2023**, 18, e0277867 ○
- 3 Is Surgical Repair With Nerve Allograft More Cost-Effective Than Non-Surgical Management for Persistent Trigeminal Neuropathy? Initial Assessment With Markov Model. **2023**, ○
- 2 Research Consensus Panel Follow-Up: A Systematic Review and Update on Cost Research in IR. **2023**, ○
- 1 Introduction to Cost-Effectiveness Analysis. **2013**, 1795-1801.e1 ○